M. Russo

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

A. Makhson, P. Dubé, P. Hesketh, 2012, Supportive Care in Cancer.

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

G. Rossato, G. Vassal, O. Witt, 2022, European journal of cancer.

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Bing-he Xu, M. Desilvio, Zefei Jiang, 2014, Breast Cancer Research.

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma

B. Geoerger, C. Moertel, D. Hargrave, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC).

W. Arpornwirat, S. Grunberg, G. Ross, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Bing-he Xu, M. Desilvio, Zefei Jiang, 2014, Breast Cancer Research.

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis

B. Geoerger, D. Hargrave, M. Roughton, 2023, Blood advances.

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma

O. Witt, A. Kieloch, D. Hargrave, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.

U. Tabori, E. Bouffet, F. Sahm, 2023, The New England journal of medicine.

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition

J. Fangusaro, J. Kilday, A. Waanders, 2024, Neuro-oncology.